Trial reportThe Journal of allergy and clinical immunology2010
Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.
Trial report in The Journal of allergy and clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 55 citations in OpenAlex.
- Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.The Journal of allergy and clinical immunology · 2017Trial
- Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.The Journal of allergy and clinical immunology · 2013Trial
- The Potential Role of Basophils in Urticaria.Frontiers in immunology · 2022Review
- Basophils from allergy to cancer.Frontiers in immunology · 2022Review
- Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy.Frontiers in immunology · 2021Review
- The relationship between released soluble FceRI-alpha and its cell surface density on human basophils.PloS one · 2021Article
- Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children.Asia Pacific allergy · 2019Review
- Basophil Activation Test: Old and New Applications in Allergy.Current allergy and asthma reports · 2018Review
- IL-3 but not monomeric IgE regulates FcεRI levels and cell survival in primary human basophils.Cell death & disease · 2018Article
- Road map for the clinical application of the basophil activation test in food allergy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2017Review
- Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.Allergy · 2017Review
- Article
- Stability of Syk protein and mRNA in human peripheral blood basophils.Journal of leukocyte biology · 2016Article
- New insights into basophil heterogeneity.Seminars in immunopathology · 2016Review
- Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases.The Journal of allergy and clinical immunology · 2016Review
- Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.Nature communications · 2016Article
- Article
- Immunotherapy in allergy and cellular tests: state of art.Human vaccines & immunotherapeutics · 2014Review
- Omalizumab, an anti-immunoglobulin E antibody: state of the art.Drug design, development and therapy · 2014Article
- Basophils and allergic inflammation.The Journal of allergy and clinical immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundIn human basophils from different subjects, maximum IgE-mediated histamine release and the level of Syk protein expression correlate well. Recent studies suggest that in some patients treated with omalizumab, the response to stimulation with anti-IgE antibody increases. In unrelated studies there is also evidence that the composition of FcepsilonRI in basophils differs among subjects. This observation raised the possibility that the stoichiometry of FcRbeta/FcepsilonRIalpha is not fixed to a 1:1 ratio and might be modifiable during changes in the basophil's environment.
objectiveWe sought to determine whether treatment with omalizumab results in increases in Syk expression and anti-IgE-mediated histamine release and disproportionately alters the relative presence of FcRbeta and FcepsilonRIalpha.
methodSyk, FcepsilonRIalpha, and FcRbeta expression was monitored during the treatment of subjects with omalizumab.
resultsTreatment with omalizumab reduced histamine release from peripheral blood leukocytes stimulated with cat allergen in vitro, but histamine release stimulated with anti-IgE antibody increased 2-fold. Expression of Syk increased 1.86-fold. There was no change in the expression of c-Cbl, a signaling element that is sensitive to the presence of IL-3, and no increase in response to formyl-met-leu-phe (tripeptide), a response that also increases in the presence of IL-3. There was a 60% decrease in the FcRbeta/FcepsilonRIalpha ratio in patients treated with omalizumab.
conclusionsIn the context of previous studies, these studies provide support for a proposal that Syk expression is modulated in vivo through an IgE-dependent mechanism and that the ratio of FcepsilonRI alpha and beta subunits in basophils is influenced by factors extrinsic to the cell.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.